Company intelligence / Profile preview

Optovue

Fremont, California, United Statesvisionix.com ↗

Ownership: Private
Development stage: Commercial

Overview

Optovue pioneered commercial optical coherence tomography angiography ("OCTA") with its AngioVue system, enabling non-invasive visualization of retinal blood vessels. Its technologies are used worldwide for diagnosing and managing major causes of blindness such as diabetic retinopathy and wet AMD. The company has over 225 peer-reviewed publications supporting its technology's clinical value.

Therapeutic areas: Ophthalmology
Modalities: Device
Industry: Medical Imaging

Partnerships

Delta Electronics investment via Deltronics subsidiary ($30M funding round in 2015); no major pharma partnerships reported.

Beyond the preview

Go deeper on Optovue.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Optovue.

Explore the full profile